Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Rimonabant research shows mixed picture

Rimonabant has some benefits at reducing risk factors for heart disease in obese patients, but the overall picture is mixed, international research concludes.

A randomised controlled trial comparing rimonabant with placebo in 839 patients found no significant reduction for percentage atheroma volume, but did find the drug significantly reduced total atheroma volume, over 18 months.

The research also found an increase in HDL cholesterol levels of 22.4% for patients on rimonabant compared with 6.9% for controls, but LDL cholesterol levels and blood pressure changes did not differ significantly between treatment groups.

JAMA 2008;299:1547-60

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say